Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

Published:2022-11-29 Issue:1 Volume:7 Page:48-54
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Tan Chee‐Kiat¹^ORCID,Luo Xue‐Shi²,Ong Benjamin Shao‐Kiat²,Lin Liang²,Ng Kwong‐Hoe²

Affiliation:

1. Department of Gastroenterology and Hepatology Singapore General Hospital Singapore

2. Agency for Care Effectiveness, Ministry of Health Singapore

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12850

Reference27 articles.

1. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

2. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

3. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection

4. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

5. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP